论文部分内容阅读
目的:探讨血管紧张素转化酶抑制剂(ACEI)在小儿肾脏疾病中的应用,为规范该类药物在IgA肾病中的超说明书应用提供参考依据。方法:回顾性分析2014年12月16日1例7岁IgA肾病患儿的病例资料,结合最新的临床证据,从超说明书用药角度分析和评价贝那普利在IgA肾病儿童患儿中的应用,探讨并明确ACEI类药物在慢性肾病患者中的应用指征、剂量及疗程等超说明书用药内容。结果:贝那普利具有不依赖于降血压的降蛋白作用,在应用ACEI类药物时需要监测肾功能以评估病情变化并调整药物剂量。结论:ACEI类药物在儿童肾脏病中有积极的治疗作用,应严格把握该类药物的超说明书用药指征,加强临床观察和药学监护,确保用药安全。
Objective: To investigate the application of angiotensin converting enzyme inhibitor (ACEI) in pediatric kidney disease and to provide a reference for regulating the application of these drugs in the super instruction of IgA nephropathy. Methods: A retrospective case history of a 7-year-old child with IgA nephropathy was retrospectively analyzed on December 16, 2014. According to the latest clinical evidence, the application of benazepril in children with IgA nephropathy , To explore and clear ACEI drugs in patients with chronic kidney disease indications, dosage and course of treatment and other super instructions content. Results: Benazepril has a hypotensive effect that is independent of blood pressure. In the application of ACEIs, renal function needs to be monitored to assess the patient’s condition and adjust the dosage. CONCLUSION: ACEI drugs have a positive therapeutic effect in children with kidney disease. Strict indications should be strictly given for the use of such drugs, and clinical observation and pharmacy monitoring should be strengthened to ensure drug safety.